Structure-based predictive model for some benzimidazole inhibitors of hepatitis C virus NS5B polymerase

Medicinal Chemistry Research

Volumn 22, Issue 4, 2013, Pages 1866-1883

  Mahmoud, Amr H ^a   Elsayed, Mohamed S A ^a   Elhefnawi, Mahmoud ^b,c  

^a African Union Organization St Abbassia   (Egypt)

^b NATIONAL RESEARCH CENTRE   (Egypt)

^c Egypt Japan University of Science and Technology   (Egypt)

Author keywords

Docking; HCV polymerase; JTK 109; Pharmacophore

Indexed keywords

ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; JTK 109; NONSTRUCTURAL PROTEIN 5B; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; BINDING KINETICS; COMPARATIVE MOLECULAR FIELD ANALYSIS; CORRELATION ANALYSIS; DRUG SCREENING; HEPATITIS C; HEPATITIS C VIRUS; HYDROGEN BOND; MOLECULAR DOCKING; PHARMACOPHORE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RECEIVER OPERATING CHARACTERISTIC; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

EID: 84879693663     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-012-0186-8     Document Type: Article

References (52)

1. Accelrys (2010) Accelry's discovery studio 2.5.5 Accelrys Software, San Diego
2. Accelrys (2010) Accelry's discovery studio 3.0. Accelrys, San Diego
3. Accelrys (2010) Accelrys pipeline pilot. Accelrys, San Diego
4. Aqvist J, Medina C, Samuelsson JE (1994) A new method for predicting binding affinity in computer-aided drug design. Protein Eng 7(3):385-391. doi: 10.1093/protein/7.3.385
5. Beaulieu PLTY (2004) Inhibitors of the HCV NS5B polymerase: new hope for the treatment of hepatitis C infections. Curr Opin Investig Drugs 5(8):838-850
6. Beaulieu PL (2006) The discovery of finger loop inhibitors of the hepatitis C virus NS5B polymerase: status and prospects for novel HCV therapeutics. IDrugs Investig Drugs J 9(1):39-43
7. Beaulieu PL (2009) Recent advances in the development of NS5B polymerase inhibitors for the treatment of hepatitis C virus infection. Exp Opin Ther Pat 19(2):145-164. doi: 10.1517/13543770802672598
8. Beaulieu PL, Jolicoeur E, Gillard J, Brochu C, Coulombe R, Dansereau N, Duan J, Garneau M, Jakalian A, Kuhn P, Lagace L, LaPlante S, McKercher G, Perrault S, Poirier M, Poupart MA, Stammers T, Thauvette L, Thavonekham B, Kukolj G (2010) N-Acetamideindolecarboxylic acid allosteric 'finger-loop' inhibitors of the hepatitis C virus NS5B polymerase: discovery and initial optimization studies. Bioorg Med Chem Lett 20(3):857-861. doi: 10.1016/j.bmcl.2009.12.101
9. Berendsen HJC, Postma JPM, Gunsteren WFV, DiNola A, Haak JR (1984) Molecular dynamics with coupling to an external bath. J Chem Phys 81(8):3684-3690. doi: 10.1063/1.448118
10. Bos F, Uhrig U, Masek B, Damewood J (2011) Muse + TriposScore: a ligand-based de novo design approach. J Cheminform 3(Suppl 1):P26. doi: 10.1186/1758-2946-3-S1-P26
11. Brooks BR, Bruccoleri RE, Olafson BD, States DJ, Swaminathan S, Karplus M (1983) CHARMM: a program for macromolecular energy, minimization, and dynamics calculations. J Comput Chem 4(2):187-217. doi: 10.1002/jcc.540040211
12. Cao H, Cao R, Zhang H, Zheng X, Gao D (2008) Non-nucleoside inhibitors of NS5B polymerase binding to allosteric sites: 3D- QSAR and molecular docking studies. Curr Med Chem 15(15):1462-1477
13. Carlson HA, Jorgensen WL (1995) An extended linear-response method for determining free-energies of hydration. J Phys Chem 99(26):10667-10673. doi: 10.1021/j100026a034
14. Cramer RD (2003) Topomer CoMFA: a design methodology for rapid lead optimization. J Med Chem 46(3):374-388. doi: 10.1021/Jm020194o
15. Debye P (1909) Näherungsformeln für die Zylinderfunktionen für große Werte des Arguments und unbeschränkt veränderliche Werte des Index. Math Ann 67(4):535-558. doi: 10.1007/bf01450097
16. Di Marco S, Volpari C, Tomei L, Altamura S, Harper S, Narjes F, Koch U, Rowley M, De Francesco R, Migliaccio G, Carfi A (2005) Interdomain communication in hepatitis C virus polymerase abolished by small molecule inhibitors bound to a novel allosteric site. J Biol Chem 280(33):29765-29770. doi: 10.1074/jbc.M505423200
17. Dixon SL, Smondyrev AM, Rao SN (2006) PHASE: a novel approach to pharmacophore modeling and 3D database searching. Chem Biol Drug Des 67(5):370-372. doi: 10.1111/j.1747-0285.2006.00384.x
18. Fletcher R, Reeves CM (1964) Function minimization by conjugate gradients. Comput J 7(2):149-154. doi: 10.1093/comjnl/7.2.149
19. Gehlhaar DK, Verkhivker GM, Rejto PA, Sherman CJ, Fogel DB, Fogel LJ, Freer ST (1995) Molecular recognition of the inhibitor Ag-1343 by Hiv-1 protease - conformationally flexible docking by evolutionary programming. Chem Biol 2(5):317-324. doi: 10.1016/1074-5521(95)90050-0
20. Gentles RG, Sheriff S, Beno BR, Wan CH, Kish K, Ding M, Zheng XF, Chupak L, Poss MA, Witmer MR, Morin P, Wang YK, Rigat K, Lemm J, Voss S, Liu MP, Pelosi L, Roberts SB, Gao M, Kadow JF (2011) Investigation of the mode of binding of a novel series of N-benzyl-4-heteroaryl-1-(phenylsulfonyl)piperazine-2- carboxamides to the hepatitis C virus polymerase. Bioorg Med Chem Lett 21(8):2212-2215. doi: 10.1016/j.bmcl.2011.03.011
21. Glide (2009) CombiGlide, version 2.5, 5th edn. Schrodinger, New York
22. Hallowita N, Udonkang E, Ruan C, Frieler CE, Rodgers MT (2009) Inductive effects on cation-π interactions: structures and bond dissociation energies of alkali metal cation-halobenzene complexes. Int J Mass Spectrom 283(1-3):35-47. doi: 10.1016/j.ijms.2009.01.006
23. Hirashima S, Suzuki T, Ishida T, Noji S, Yata S, Ando I, Komatsu M, Ikeda S, Hashimoto H (2006) Benzimidazole derivatives bearing substituted biphenyls as hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors: structure-activity relationship studies and identification of a potent and highly selective inhibitor JTK-109. J Med Chem 49(15):4721-4736. doi: 10.1021/jm060269e
24. Hirashima S, Oka T, Ikegashira K, Noji S, Yamanaka H, Hara Y, Goto H, Mizojiri R, Niwa Y, Noguchi T, Ando I, Ikeda S, Hashimoto H (2007) Further studies on hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors toward improved replicon cell activities: benzimidazole and structurally related compounds bearing the 2-morpholinophenyl moiety. Bioorg Med Chem Lett 17(11):3181-3186. doi: 10.1016/j.bmcl.2007.03.027
25. Huang D, Caflisch A (2004) Efficient evaluation of binding free energy using continuum electrostatics solvation. J Med Chem 47(23):5791-5797. doi: 10.1021/Jm049726m
26. Jain AN (1996) Scoring noncovalent protein-ligand interactions: a continuous differentiable function tuned to compute binding affinities. J Comput Aided Mol Des 10(5):427-440. doi: 10.1007/bf00124474
27. Jones G, Willett P, Glen RC, Leach AR, Taylor R (1997) Development and validation of a genetic algorithm for flexible ligand docking. Abstr Pap Am Chem Soc 214:154-COMP. doi: 10.1.1.130.3377
28. LaPlante SR, Gillard JR, Jakalian A, Aubry N, Coulombe R, Brochu C, Tsantrizos YS, Poirier M, Kukolj G, Beaulieu PL (2010) Importance of ligand bioactive conformation in the discovery of potent indole-diamide inhibitors of the hepatitis C virus NS5B. J Am Chem Soc 132(43):15204-15212. doi: 10.1021/Ja101358s
29. Legrand-Abravanel F, Nicot F, Izopet J (2010) New NS5B polymerase inhibitors for hepatitis C. Exp Opin Invest Drugs 19(8):963-975. doi: 10.1517/13543784.2010.500285
30. Liu T, Lin Y, Wen X, Jorissen RN, Gilson MK (2007) BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucl Acid Res 35(suppl 1):D198-D201. doi: 10.1093/nar/gkl999
31. Mahmoud AH, Abou El Ella DA, Ismail MAH, Abouzid KAM (2012) A highly selective structure-based virtual screening model of Palm I allosteric inhibitors of HCV Ns5b polymerase enzyme and its application in the discovery and optimization of new analogues. Eur J Med Chem. doi: 10.1016/j.ejmech.2012. 04.016
32. Mayo SL, Olafson BD, Goddard WA (1990) DREIDING: a generic force field for molecular simulations. J Phys Chem 94(26):8897-8909. doi: 10.1021/j100389a010
33. Melnikova I (2008) Hepatitis C therapies. Nat Rev Drug Discov 7(10):799-800. doi: 10.1038/nrd2661
34. ® force field. J Comput Chem 13(7):888-900. doi: 10.1002/jcc.540130714
35. Muegge I (2005) PMF scoring revisited. J Med Chem 49(20):5895-5902. doi: 10.1021/jm050038s
36. Narjes F, Crescenzi B, Ferrara M, Habermann J, Colarusso S, Ferreira MDR, Stansfield I, Mackay AC, Conte I, Ercolani C, Zaramella S, Palumbi MC, Meuleman P, Leroux-Roels G, Giuliano C, Fiore F, Marco S, Baiocco P, Koch U, Migliaccio G, Altamura S, Laufer R, De Francesco R, Rowley M (2011) Discovery of (7R)-14-cyclohexyl-7-{[2-(dimethylamino)ethyl](methyl) amino}-7,8-dihydro-6H- indolo[1,2-e][1,5]benzoxazocine-11-carboxylic acid (MK-3281), a potent and orally bioavailable finger-loop inhibitor of the hepatitis C virus NS5B polymerase. J Med Chem 54(1):289-301. doi: 10.1021/jm1013105
37. Patel PD, Patel MR, Kaushik-Basu N, Talele TT (2008) 3D QSAR and molecular docking studies of benzimidazole derivatives as hepatitis C virus NS5B polymerase inhibitors. J Chem Inform Model 48(1):42-55. doi: 10.1021/ci700266z
38. Perz JF, Armstrong GL, Farrington LA, Hutin YJF, Bell BP (2006) The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45(4):529-538. doi: 10.1016/j.jhep.2006.05.013
39. Salam NK, Nuti R, Sherman W (2009) Novel method for generating structure-based pharmacophores using energetic analysis. J Chem Inform Model 49(10):2356-2368. doi: 10.1021/ci900212v
40. Schrödinger (2009) Schrödinger 2009 update 2, 2nd edn. Schrödinger, New York
41. Seeliger D, de Groot BL (2010) Conformational transitions upon ligand binding: holo-structure prediction from apo conformations. PLoS Comput Biol 6(1):e1000634. doi: 10.1371/journal.pcbi.1000634
42. Singh P, Mhaka AM, Christensen SB, Gray JJ, Denmeade SR, Isaacs JT (2005) Applying linear interaction energy method for rational design of noncompetitive allosteric inhibitors of the sarco- and endoplasmic reticulum calcium-ATPase. J Med Chem 48(8):3005-3014. doi: 10.1021/jm049319a
43. Talele TT (2008) Multiple allosteric pockets of HCV NS5B polymerase and its inhibitors: a structure-based insight. Curr Bioact Compd 4(2):86-109. doi: 10.2174/157340708785294217
44. Tounge BA, Reynolds CH (2003) Calculation of the binding affinity of beta-secretase inhibitors using the linear interaction energy method. J Med Chem 226:U444
45. Tripos International (2011) Sybyl-X 1.2. Tripos International, St. Louis
46. Verlet L (1967) Computer "experiments" on classical fluids. I. Thermodynamical properties of Lennard-Jones molecules. Phys Rev 159(1):98. doi: 10.1103/PhysRev.159.98
47. Walker MP, Hong Z (2002) HCV RNA-dependent RNA polymerase as a target for antiviral development. Curr Opin Pharm 2(5):534-540. doi: 10.1016/s1471- 4892(02)00195-9
48. Wallach I, Lilien R (2011) Virtual decoy sets for molecular docking benchmarks. J Chem Inform Model 51(2):196-202. doi: 10.1021/Ci100374f
49. Wolber G, Langer T (2005a) LigandScout: 3-d pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J Chem Inform Model 45(1):160-169. doi: 10.1021/Ci049885e
50. Wolber G, Langer T (2005b) LigandScout: interactive automated pharmacophore model generation from ligand-target complexes. Abstr Pap Am Chem Soc 229:U611
51. Zheng XF, Hudyma TW, Martin SW, Bergstrom C, Ding M, He F, Romine J, Poss MA, Kadow JF, Chang CH, Wan J, Witmer MR, Morin P, Camac DM, Sheriff S, Beno BR, Rigat KL, Wang YK, Fridell R, Lemm J, Qiu D, Liu MP, Voss S, Pelosi L, Roberts SB, Gao M, Knipe J, Gentles RG (2011) Syntheses and initial evaluation of a series of indolo-fused heterocyclic inhibitors of the polymerase enzyme (NS5B) of the hepatitis C virus. Bioorg Med Chem Lett 21(10):2925-2929. doi: 10.1016/j.bmcl.2011.03.067
52. Zhou RH, Friesner RA, Ghosh A, Rizzo RC, Jorgensen WL, Levy RM (2001) New linear interaction method for binding affinity calculations using a continuum solvent model. J Phys Chem B 105(42):10388-10397. doi: 10.1021/Jp011480z